v3.26.1
Segment Information
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

Note 10. Segment Information

The Company’s Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), manages the business through two operating segments, consistent with how the Company’s Chief Executive Officer: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions, and (iii) designates responsibilities of his direct reports. The Company’s operating segments, which were renamed in 2025, and which also qualify as reportable segments include: (i) Interventional Glaucoma (formerly “Surgical Glaucoma”) and (ii) Interventional Dry Eye (formerly “Dry Eye”). The change in names of the operating segments has no impact on how the CODM manages the business. These segments are generally determined based on the decision-making structure and the grouping of similar products and services.

The Company’s CODM uses segment gross profit to assess the operating performance and make resource allocation decisions for each of its segments. Segment gross profit represents revenue reduced by cost of goods sold within each of the operating and reportable segments. The CODM reviews a monthly executive reporting package based on consolidated results of the Company when making decisions about allocating resources and assessing performance. The CODM evaluates actual segment performance to budget and forecast, including monthly sales performance, when allocating capital and personnel.

The Company does not have any intercompany transactions between segments that require elimination. The CODM does not review operating expenses separately for its segments, as the Company does not allocate operating expenses, with many operating costs shared between the segments, and therefore, this is not considered when allocating resources and assessing performance. The Company evaluated the monthly executive reporting package and did not identify any significant or other expenses for disclosure that are not already presented.

In reviewing and assessing segment performance and managing operations, management does not review segment assets. Substantially all of the Company’s revenue is generated from sales in the United States.

The following table summarizes select operating results information for each reportable segment (in thousands):

 

 

Three Months Ended
March 31,

 

 

 

2026

 

 

2025

 

Revenue

 

 

 

 

 

 

Interventional Glaucoma

 

$

18,344

 

 

$

17,114

 

Interventional Dry Eye

 

 

1,354

 

 

 

394

 

Total

 

 

19,698

 

 

 

17,508

 

Cost of goods sold

 

 

 

 

 

 

Interventional Glaucoma

 

 

2,342

 

 

 

2,298

 

Interventional Dry Eye

 

 

378

 

 

 

116

 

Total

 

 

2,720

 

 

 

2,414

 

Gross profit

 

 

 

 

 

 

Interventional Glaucoma

 

 

16,002

 

 

 

14,816

 

Interventional Dry Eye

 

 

976

 

 

 

278

 

Total

 

 

16,978

 

 

 

15,094

 

Operating expense

 

 

(29,391

)

 

 

(28,953

)

Investment income

 

 

741

 

 

 

1,148

 

Interest expense

 

 

(1,268

)

 

 

(1,263

)

Other expense, net

 

 

(29

)

 

 

(139

)

Loss before income taxes

 

$

(12,969

)

 

$

(14,113

)